Expanded Collaboration Agreement to Make
Less Invasive Blood Sample Collection More Convenient and Patient
Centered
AUSTIN,
Texas and FRANKLIN LAKES,
N.J., May 11, 2022 /PRNewswire/ -- Babson
Diagnostics, a science-first, health care technology company, and
BD (Becton, Dickinson and Company)
(NYSE: BDX), a leading global medical technology company, today
announced the expansion of a strategic partnership to move blood
sample collection into new care settings, including enabling
patients to collect blood samples at home for diagnostic
testing.
Since 2019, the two companies have collaborated to create a
capillary blood collection and testing system, now in advanced
development, to enable laboratory-quality, small-volume capillary
blood collection at retail settings by team members with no
previous experience in blood collection. Plans under the expanded
agreement include continuing research and development to enable
self-collection, mobile services and at-home collection. Babson and
BD also will expand the types of blood tests that are possible
through small-volume blood collection beyond primary care-oriented
tests, and they also plan to develop diagnostic tests for pediatric
use.
"Today's agreement expands our long-standing partnership with BD
and builds on our shared passion of making convenient blood testing
accessible to all, not only in the U.S., but also globally," said
David Stein, chief executive officer
of Babson Diagnostics. "Extending the medical home is critical in
today's health care environment. We believe that retail convenience
is perfect for today's consumer, but because the Babson service is
well-suited to many settings with no need for a phlebotomist and an
easier collection experience, we see many opportunities for future
expansion."
Over this long-term collaboration, Babson and BD are advancing
development of the blood testing ecosystem, which includes BD's
next generation capillary collection technology and Babson's
proprietary automated sample-handling and analytical technologies.
These have been designed to work together to enable blood testing
that requires only one-tenth the sample volume of traditional
venipuncture methods without sacrificing quality, accuracy, or the
number and types of tests that are possible.
"This is a paradigm-shifting solution that addresses multiple
unmet needs within the current health care system," said
Brooke Story, president of
Integrated Diagnostics Solutions for BD. "Because it is less
invasive and more convenient than the traditional venous blood draw
method, capillary blood collection may lead to an improved patient
experience, which in turn could help health care providers see
better compliance among patients for routine blood testing."
BD brings 70 years of specimen management experience to the
partnership and is a leader in blood collection technology,
including the development of the new, state-of-the-art capillary
collection devicei. Babson provides deep instrument
analyzer expertise and is building an ecosystem for blood
collection in the pharmacy setting as well as designing the systems
and workflows to analyze small volume capillary blood in a central
lab. Babson continues to work with local and national pharmacy
chains to conduct extensive clinical studies of its service
platform in preparation for commercial launch.
About Babson Diagnostics
Babson Diagnostics is a health care technology company rooted in
science reimagining the entire diagnostic blood testing experience.
Babson's mission is to make routine blood testing less invasive,
more convenient and affordable, empowering people to take charge of
their health.
Babson will bring medically accurate blood testing to the retail
pharmacy by using patented technologies and a first-of-its-kind
ecosystem that requires only one-tenth the sample volume of
traditional venipuncture methods without sacrificing quality,
accuracy, or menu breadth.
The company has received key patents in the United States, European Union, and
China related to its unique
end-to-end technological ecosystem and the ability to maximize the
clinical utility of microsamples of blood collected from a
fingertip. In addition, Babson has fully validated a broad set of
miniaturized assays that are ready for commercial use in its
CLIA-certified laboratory.
Babson, based in Austin, Texas,
was founded by individuals with deep experience in healthcare,
diagnostics, engineering, and laboratory technologies. It is named
in honor of Art Babson, whose legacy
of scientific innovation and excellence is the foundation on which
the company is built.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 75,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Babson
|
|
Joe Foster
|
|
Babson Diagnostics
Media
|
|
BabsonDX@finnpartners.com
|
|
323-572-5361
|
|
|
|
BD
Media
|
BD Investor
Relations
|
Troy Kirkpatrick
|
Francesca
DeMartino
|
VP, Public
Relations
|
SVP, Head of Investor
Relations
|
858.617.2361
|
201.847.5743
|
troy.kirkpatrick@bd.com
|
francesca.demartino@bd.com
|
i The capillary collection device is an
investigational device under 21 C.F.R. 812 and requires additional
studies to make any definitive conclusions about safety or
efficacy
View original content to download
multimedia:https://www.prnewswire.com/news-releases/babson-bd-expand-strategic-partnership-to-advance-diagnostic-blood-collection-in-new-care-settings-301544697.html
SOURCE BD (Becton, Dickinson
and Company)